Life Sciences

Against a backdrop of geopolitical tension, valuation resets and shifting capital markets, life sciences dealmaking is not slowing, it is recalibrating. The tone at...

Since Stifel’s acquisition of Bryan Garnier in 2025, the US-based full-service firm has accelerated the build-out of its European platform, emerging as financial adviser...

For decades, the medical technology sector has been defined by product innovation. Companies competed by developing devices that were incrementally better: a more precise...

Luca Gambini, partner, and Claudio Todisco, associate, at Portolano Cavallo - an Italy-based full-service law firm operating in complex and evolving sectors and a...

In February 2026, a group of European life sciences investors, research institutions, and ecosystem partners launched the European Life Sciences Coalition (ELSC) in association...

After years of market turbulence, healthcare investors are cautiously eyeing 2026 as a potential turning point. But the path forward is anything but uniform....

To attract global investment and foster innovation in its life sciences sector, Britain must reshape its legal and policy frameworks, writes Clare Auty, partner...

Life sciences in Europe and beyond present investors a dynamic landscape of opportunity, innovation - and risk. Biotech breakthroughs, innovative medical devices, and digital...

On 25 September, hundreds of healthcare professionals, investors, and industry leaders gathered in London for McDermott Will & Schulte’s Healthcare Private Equity (HPE) Europe...

Long overlooked by mainstream investors, women’s health is finally attracting serious attention. With sustained growth, rising consumer demand, and a shift toward preventive and...